Dr. Manuel Carcao
MD, MSc
Biography
Dr. Carcao is a Haematologist in the Division of Haematology/Oncology, and Professor of Paediatrics at the University of Toronto. He is Director of the Haemophilia and Bleeding disorders’ program at the Hospital for Sick Children.
Dr. Carcao received his medical degree in 1990 and a Master of Science degree in Clinical Epidemiology in 2007 from the University of Toronto. He joined the division of Haematology/Oncology as a faculty member in 1999.
Dr Carcao was President of the Association of Hemophilia Clinic Directors of Canada (2006-08) and Chair of the Canadian Paediatric Thrombosis & Haemostasis Network (2016-18). He is the author of over 200 peer-reviewed papers and textbook chapters. He is a prolific speaker giving talks throughout the world including plenary sessions at WFH, ISTH and other international meetings.
His research interests include congenital bleeding disorders, genetics, prophylaxis needs, pharmacokinetics, and inhibitor development; childhood immune thrombocytopenia; hereditary spherocytosis and more recently in the medical management of vascular malformations.
In 2023 he was awarded the Hak-Ming and Deborah Chiu Chair in Paediatric Translational Research – a 5-10 year chair whose goal is to develop a Vascular Anomalies program and center.
Key Publications
-
Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25(4):676-684.
-
Carcao MD, Chelle P, Clarke E, et al. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. J Thromb Haemost. 2019;17(7):1085-1096.
-
Carcao M, Mancuso ME, Young G, Jiménez-Yuste V. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021;14(2):143-148.
-
Königs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results [published correction appears in Blood. 2023 Mar 23;141(12):1495]. Blood. 2022;139(26):3699-3707.
Key Institutions
-
The Hospital for Sick Children
Division of Haematology/ Oncology
Toronto, Canada
Current Positions/Chairs
-
Paediatric Haematologist/Oncologist
Division of Haematology/ Oncology -
Professor
Department of Paediatrics at the Hospital for Sick Children -
Director
Haemophilia Clinic and Haemostasis Program -
Associate Scientist/Clinician Investigator
Research Institute at the Hospital for Sick Children -
Chair
Hak-Ming and Deborah Chiu Chair in Paediatric Translational Research -
Member
International Prophylaxis Study Group-Prophylaxis Expert Working Group
Research Interests
-
Congenital bleeding disorders
-
Genetics
-
Prophylaxis needs
-
Pharmacokinetics
-
Inhibitor development
-
Childhood immune thrombocytopenia
-
Hereditary spherocytosis
-
Medical management of vascular malformations
Achievements
-
Melpadom Attumalil Georgekutty Young Scientist Award-2013 of the Marthoma Church taking into consideration of outstanding contribution in the field of Science and Technology
Publications
Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis
Authors
Carcao M, Lambert T, Leissinger C, Escuriola-Ettingshausen C, Santagostino E, Aledort L; International Prophylaxis Study Group (IPSG).
Citation
Haemophilia. E-Pub July 10, 2018
An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia
Authors
Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.
Citation
Haemophilia 2017; 23 (5) : e444 - e447
An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia
Authors
Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators
Citation
Haemophilia 2017; 23 (5):e447 - e450
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors).
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators
Citation
57th American Society of Hematology Meeting 2015.
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
Prophylaxis in adult patients with severe hemophilia A or B without inhibitors.
Authors
Carcao, M on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators.
Prophylaxis practices in children and adults with inhibitors.
Authors
Carcao M, Avila M, Aledort L, Leissinger C on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators
Citation
Journal of Thrombosis and Haemostasis 2015, 13 (S2), # PO270-MON, 360.
Inter-reader reliability of minimum and full MRI protocols for interpretation of findings in hemophilic arthropathy in children.
Authors
Castro D, Lundin B, Zhang N, Ignas D, Carcao M, Moineddin R, Man C, Blanchette VS, and Doria AS
Citation
Haemophilia 2014, 20 (S3), 89
Hemophilia Prophylaxis: How can we justify the costs?
Authors
Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan A, and Schramm W.
Citation
Haemophilia 2012 Sept; 18 (5): 680-684.
A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG).
Authors
Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.
Citation
Haemophilia 2008, 14 (S2), 133 # 24 PO 17.
A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG)
Authors
Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.
Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of the International Prophylaxis Study Group.
Authors
Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Mantovani L, Hoots K,, Schramm W, van Hout BA, Willan AR, and Feldman BM.
Citation
Haemophilia 2008 Jan; 14 (1):127 -132.